48 completed. 48 Phase 2, 9 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 48 | Completed 48 |
| Phase 1 | 9 | Completed 9 |
| Phase 3 | 2 | Completed 2 |
Follow Enterobacteriaceae Infections: new trials by email Literature Review of Enterobacteriaceae Infections trials Research Report on Enterobacteriaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. Shigella4V2, MenACWY - Shigellosis | Phase 2 | Completed | LimmaTech Biologics AG | 110 | 2025-04-07 | 2026-08-07 |
| Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever Levofloxacin, ciprofloxacin - Typhoid, Fever | Phase 2 | Completed | Avicenna Medical College Lahore | 360 | 2025-02-07 | 2025-09-02 |
| A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants altSonflex1-2-3 Dose A, altSonflex1-2-3 Dose B, altSonflex1-2-3 Dose C - Diarrhoea | Phase 2 | Completed | GlaxoSmithKline | 200 | 2024-11-13 | 2026-10-26 |
| A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine Shigella4V2, Placebo - Shigellosis | Phase 2 | Completed | LimmaTech Biologics AG | 97 | 2024-11-12 | 2026-10-01 |
| PMT for MDRO Decolonization PMT - Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections | Phase 2 | Completed | University of Pennsylvania | 32 | 2024-08-19 | 2026-09-24 |
| Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso Vi capsular polysaccharide-CRM197 conjugate vaccine (Vi-CRM), 0.5 mL IM - Typhoid | Phase 2 | Completed | Kathleen Neuzil | 147 | 2024-08-17 | 2026-06-03 |
| A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants iNTS-GMMA Dose C, iNTS-GMMA Dose B, iNTS-GMMA Dose A - Salmonella Infections | Phase 2 | Completed | GlaxoSmithKline | 180 | 2024-01-15 | 2026-09-21 |
| Phase 2 Shigella Vaccine and Challenge Placebo, Shigella sonnei strain 53G, WRSs2 - Immunisation, Shigella Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 69 | 2022-10-12 | 2026-08-10 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose - Salmonella Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 155 | 2022-09-13 | 2025-11-28 |
| Tebipenem Trial in Children With Shigellosis Tebipenem Pivoxil, Azithromycin, Ceftriaxon - Shigellosis | Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 132 | 2022-08-18 | 2026-09-01 |
| Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age rF1V-1018, rF1V vaccine - Plague, Pneumonic, Plague | Phase 2 | Completed | Dynavax Technologies Corporation | 200 | 2022-08-09 | 2025-07-29 |
| Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) - Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 630 | 2022-07-01 | 2024-12-24 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a Injection SF2A-TT15 10 µg Adjuvanted, Injection SF2A-TT15 10 µg, Injection Adjuvanted Placebo - Healthy | Phase 2 | Completed | Institut Pasteur | 248 | 2020-10-06 | 2024-04-23 |
| Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV - Typhoid Fever | Phase 2 / Phase 3 | Completed | EuBiologics Co.,Ltd | 444 | 2020-09-07 | 2021-10-07 |
| Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine SF2a-TT15 Shigella Vaccine, Placebo, S. flexneri 2a strain 2457T Challenge Agent - Shigella | Phase 2 | Completed | University of Maryland, Baltimore | 58 | 2020-03-02 | 2024-05-20 |
| A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Shigella 4V, MenACWY, Rabies - Shigellosis | Phase 1 / Phase 2 | Completed | LimmaTech Biologics AG | 597 | 2019-09-02 | 2026-06-23 |
| Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine, Haemophilus b Conjugate Vaccine - Dysentery, Dysentery, Bacillary | Phase 2 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 1050 | 2019-01-19 | 2022-01-13 |
| Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Vi-Typhoid Conjugate Vaccine (Vi-TCV), Inactivated Poliovirus Vaccine (IPV) - Typhoid | Phase 2 | Completed | University of Maryland, Baltimore | 251 | 2018-12-03 | 2025-05-30 |
| A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults S.sonnei vaccine, Placebo, S. sonnei 53G challenge strain - Dysentery, Bacillary | Phase 2 | Completed | GlaxoSmithKline | 71 | 2018-08-29 | 2020-07-28 |
Showing 20 of 48. Sign in to see all of them.
Typhoid Fever (17) · Dysentery, Bacillary (16) · Escherichia coli Infections (6) · Diarrhea (5) · Plague (5) · Dysentery (2) · Salmonella Infections (2) · Cholera (1) · Enteritis (1) · Fever (1) · Paratyphoid Fever (1) · Patient Compliance (1) · Proteus Infections (1) · Pseudomonas Infections (1)
Bacterial Infections (48) · Bacterial Infections and Mycoses (48) · Gram-Negative Bacterial Infections (48) · Infections (48) · Digestive System Diseases (17) · Gastroenteritis (17) · Gastrointestinal Diseases (17) · Intestinal Diseases (17) · Salmonella Infections (17) · Dysentery (14) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Signs and Symptoms, Digestive (5) · Vector Borne Diseases (5)
Meningococcal Vaccines (4) · Vi polysaccharide vaccine, typhoid (4) · MenACWY (3) · Vaccines (3) · diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (3) · 13-valent pneumococcal vaccine (2) · Boostrix (2) · Ciprofloxacin (2) · Pneumococcal Vaccines (2) · Polysaccharides (2) · Rubella Vaccine (2) · Sodium Chloride (2) · Tetanus Toxoid (2) · Adjuvants, Pharmaceutic (1) · Albendazole (1)
GlaxoSmithKline (5) · International Centre for Diarrhoeal Disease Research, Bangladesh (4) · LimmaTech Biologics AG (4) · Novartis (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · U.S. Army Medical Research and Development Command (3) · Centers for Disease Control and Prevention (2) · Institut Pasteur (2) · University of Maryland, Baltimore (2) · University of Oxford (2) · Avant Immunotherapeutics (1) · Avicenna Medical College Lahore (1) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1) · Charite University, Berlin, Germany (1) · DynPort Vaccine Company LLC, A GDIT Company (1)
United States (15) · Bangladesh (5) · Kenya (5) · Belgium (4) · Philippines (3) · United Kingdom (3) · Burkina Faso (2) · China (2) · Pakistan (2) · Argentina (1) · Chile (1) · France (1) · Germany (1) · Ghana (1) · Guatemala (1)
Kawsar R Talaat, MD (2) · Andrew J Pollard (1) · Andrew J Pollard, FRCPCH, PhD (1) · Armelle Phalipon, PhD (1) · Benno G Roesch (1) · Brendan J Kelly (1) · Carl Mason, MD (1) · Christiane Gerke, PhD (1) · Christopher A Smith (1) · Clark McKeever, MD (1) · Douglas R Schumacher (1) · Dr David Lewis, MD (1) · Dr Odile Launay, MD (1)
PMID 24290843, PMID 18554712, PMID 20188175, PMID 21980445, PMID 22574737, PMID 23823651, PMID 27146000, PMID 27533046, PMID 28965718, PMID 29927704, PMID 30473185, PMID 30845330, PMID 31585725, PMID 31757774, PMID 31877141, PMID 33150320, PMID 33862589, PMID 34219224, PMID 35062694, PMID 35536001, PMID 36774331, PMID 36875126, PMID 37358858, PMID 37402153, PMID 38853614, PMID 40000088, PMID 40277027, PMID 40446606, PMID 42379208, PMID 42617627